Download PDF
Hamostaseologie 1982; 02(03): 116-127
DOI: 10.1055/s-0038-1656574
Originalarbeiten
Schattauer GmbH

Prothrombinkomplexkonzentrate (Faktor II-VII-IX-X-Komplex)

Eigenscaften und klinische Anwendung
E. Lechler
1   Aus der Medizinischen Universitätsklinik Köln (Direktor: Prof. Dr. R. Gross)
› Author Affiliations
Further Information

Publication History

Publication Date:
21 June 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • LITERATUR

  • 1 Abildgaard U. A review of antithrombin III. In Collen D., Wiman B., Ver-straete M. (Hrsg.): The physiological inhibitors of blood coagulation and fibrinolysis Elsevier/North Holland; Amsterdam: 19 1979
    Google Scholar
  • 2 Abildgaard C. F., Britton M., Harrison J. Prothrombin complex concentrate (Konyne) in the treatment of hemophilic patients with factor VIII inhibitors. J. Pediatr. 1976; 88: 200.
    CrossrefPubMedGoogle Scholar
  • 3 Aggeler P. M., Hoag M. S., Kropat-kin M. L., Kaplan S.S. Problems involved in the measurement of factor IX: physiological and clinical implications. In Brinkhous K. M. (Hrsg.): The hemophilias The University of North Carolina Press; Chapel Hill: 1964: 131
    Google Scholar
  • 4 Aggeler P. M., White S. G., Glen-dening M. D., Page E. W., Leake T. B., Bates G. Plasma thromboplastin component (PTC) deficiency: a new disease resembling hemophilia. Proc. Soc. Biol. Med. 1952; 79: 692.
    CrossrefPubMedGoogle Scholar
  • 5 Agrawal B. L., Zelkowitz L., Hletko P. Acute myocardial infarction in a young hemophilic patient during therapy with factor IX concentrate and epsilon aminocaproic acid. J. Pediatr. 1981; 98: 931.
    CrossrefPubMedGoogle Scholar
  • 6 Allain J. P. Étude de l'activité »in vivo« du factor VIII ou du facteur IX après injection de différentes concentrés: application pratique. Nouv. Rev. Fr. d'Hémat. 1972; 12: 242.
    PubMedGoogle Scholar
  • 7 Allain J. P., Krieger G. R. Prothrombin-complex concentrates in treatment of classical haemophilia with factor-VIII antibody. Lancet 1975; II: 1203.
    PubMedGoogle Scholar
  • 8 Amphlett G. W., Byrne R., Castel-lino F. J. The binding of metal ions to bovine factor IX. J. Biol. Chem. 1978; 253: 6774.
    PubMedGoogle Scholar
  • 9 Aronson D. L. Factor IX complex. Sem. Thromb. Haemost. 1979; 6: 28.
    PubMedGoogle Scholar
  • 10 Aurousseau M. H., de Angelí J. L., Josso F. Antithrombin III versus prothrombin in liver cirrhosis. Haemostasis 1981; 10: 104.
    PubMedGoogle Scholar
  • 11 Bajaj S. B., Rapaport S. I., Brown S. F. Isolation and characterization of human factor VII. Activation of factor VII by Xa. J. Biol. Chem. 1981; 256: 253.
    PubMedGoogle Scholar
  • 12 Barrowcliffe T. W., Stableforth P., Dormandy K. M. Small scale preparation and clinical use of factor IX-prothrombin complex. Vox Sang 1973; 25: 426.
    CrossrefPubMedGoogle Scholar
  • 13 Barton P. G., Jackson C. M., Hana-han D. J. Relationship between factor V and activated factor X in the generation of prothrombinase. Nature 1967; 214: 923.
    CrossrefPubMedGoogle Scholar
  • 14 Bick R. L., Schmalhorst W. R., Fekete L. Disseminated intravascular coagulation and blood component therapy. Transfusion 1976; 16: 361.
    PubMedGoogle Scholar
  • 15 Bick R. L., Schmalhorst W. R., Shan-brom E. Prothrombin complex concentrate: use in controlling the hemorrhagic diathesis of chronic liver disease. Digest. Dis. 1975; 20: 741.
    CrossrefPubMedGoogle Scholar
  • 16 Bidwell E., Booth J. M., Dike G. W. R., Denson K. W. E. The preparation for therapeutic use of a concentrate of factor IX containing also factors II. VII and X. Brit. J. Haematol. 1967; 13: 568.
    PubMedGoogle Scholar
  • 17 Bidwell E., Rizza C. R., Dike G. W. R., Snape T. J. Clinical use of factor IX concentrates. Thromb. Haemost. 1976; 35: 488.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Biggs R., Bidwell E., Handley D. A., Macfarlane R. G., Trueta J., Elliot-Smith A., Dike G. W. R., Ash B. J. The preparation and assay of a Christmas-factor (factor IX) concentrate and its use in the treatment of two patients. Brit. J. Haemat. 1961; 7: 349.
    CrossrefPubMedGoogle Scholar
  • 19 Biggs R., Denson K. W. E. The fate of prothrombin and factors VII IX, and X transfused to patients deficient in these factors. Brit. J. Haemat. 1963; 9: 532.
    CrossrefPubMedGoogle Scholar
  • 20 Biggs R., Douglas A. S., Macfarlane R. G., Dacie J. V., Pitney W. R., Mers-key C., O'Brien J. R. »Christmas disease« a condition previously mistaken for haemophilia. Brit. med. J. 1952; 2: 1378.
    CrossrefPubMedGoogle Scholar
  • 21 Blatrix C., Soulier J. P. Préparation d'une fraction riche en prothrombine procon-vertine, facteur Stuart et en facteur anti-hémophilic B (fraction P.P.B.). Pathol. Biol. 1959; 7: 2477.
    PubMedGoogle Scholar
  • 22 Blatt P. M., Lundblad R. L., King-don H. S., McLean G., Roberts H. R. Throm-bogenic material in prothrombin complex concentrates. Ann. Intern. Med. 1974; 81: 766.
    CrossrefPubMedGoogle Scholar
  • 23 Breen F. A., Tullís J. L. Prothrombin concentrates in treatment of Christmas disease and allied disorders. J. Amer. Med. Ass. 1969; 208: 1848.
    CrossrefPubMedGoogle Scholar
  • 24 Buchanan G. R., Kevy S. V. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies. Pediatr. 1978; 62: 767.
    PubMedGoogle Scholar
  • 25 Bucher D., Nebelin E., Thomsen J., Stenflo J. Identification of γ-carboxy-glutamic acid residues in bovine factor IX and X and in a new vitamin K-dependent protein. FEBS Lett. 1976; 68: 239.
    PubMedGoogle Scholar
  • 26 Campbell E. W., Neff S., Bowdler A. J. Therapy with factor IX concentrate resulting in DIC and thromboembolic phenomena. Transfusion 1978; 18: 94.
    CrossrefPubMedGoogle Scholar
  • 27 Cartmile T. B., Castaldi P. A., Halliday E. J. Cardiac-valve surgery in factor-VII deficiency. Lancet I 1968; 752.
    PubMedGoogle Scholar
  • 28 Cash J. D., Owens R., Dalton R. G., Prescott R. J. Thrombogenicity of factor IX concentrates: in vitro and in vivo (rabbit) studies. Vox Sang 1978; 35: 105.
    CrossrefPubMedGoogle Scholar
  • 29 Cederbaum A. I., Blatt P. M., Roberts H. R. Intravascular coagulation with use of human prothrombin complex concentrates. Ann. Intern. Med. 1976; 84: 683.
    CrossrefPubMedGoogle Scholar
  • 30 Chandra S., Wickerhauser M. Contact factors are responsible for the thrombogenicity of prothrombin complex. Thromb. Res. 1979; 14: 189.
    CrossrefPubMedGoogle Scholar
  • 31 Coan M. H., Fournel M. A., Mozen M. M. Properties of commercial factor IX concentrates. Ann. N.Y. Acad. Sci. 1981; 370: 731.
    CrossrefPubMedGoogle Scholar
  • 32 Cohen O. Diskussion von Haanen C, McShine R. L., Kunst A. Preparation and clinical use of factor IX concentrate PPSB according to Soulier. Vox Sang 1969; 16: 408.
    PubMedGoogle Scholar
  • 33 Collen D., Semeraro N., Tricot J. P., Vermylen J. Turnover of fibrinogen. plasminogen and prothrombin during exercise in man. J. Appl. Physiol. 1977; 42: 865.
    PubMedGoogle Scholar
  • 34 Comp P.C., Esmon C. T. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J. Clin. Invest. 1981; 68: 1221.
    CrossrefPubMedGoogle Scholar
  • 35 Davey R. J., Shashaty G. G., Rath C. E. Acute coagulopathy following infusion of prothrombin complex concentrate. Amer. J. Med. 1976; 60: 719.
    CrossrefPubMedGoogle Scholar
  • 36 Davie E. W., Fujikawa K., Kurachi K., Kiesel W. The role of serine proteases in blood coagulation cascade. In Meister A. (Ed.): Advances in enzymology and related areas of molecular biology. John Wiley & Sons; New York.: 48 277 1979
    Google Scholar
  • 37 Delange C, Lagacé R. Hépatite associée à la prise de Konyne: Observation clinico-pathologique de 10 cas. Union Med. Can. 1974; 103: 1207.
    PubMedGoogle Scholar
  • 38 DeWitt R. T., Feinstein D. I. Prothrombin complex concentrate. Use in a hemophiliac with a factor VIII inhibitor. Arch. Intern. Med. 1977; 137: 1211.
    CrossrefPubMedGoogle Scholar
  • 39 Didisheim P., Loeb J., Blatrix Ch., Soulier J.-P. Preparation of a human plasma fraction rich in prothrombin proconvertin, Stuart factor and PTC and a study of its activity and toxicity in rabbits and in man. J. Lab. Clin. Med. 1959; 53: 322.
    PubMedGoogle Scholar
  • 40 van Dieijen G., Tans G., Rosing J., Hemker H. C. The role of phospholipid and factor Villa in the activation of bovine factor X. J. Biol. Chem. 1981; 256: 3433.
    PubMedGoogle Scholar
  • 41 Dike G. W. R., Bidwell E., Rizza C. R. The preparation and clinical use of a new concentrate containing factor IX pro-thrombin and factor X and of a separate concentrate containing factor VII. Brit. J. Haematol. 1972; 22: 469.
    CrossrefPubMedGoogle Scholar
  • 42 Dike G. W. R., Griffiths D., Bidwell E., Snape T. J., Rizza C. R. A factor VII concentrate for therapeutic use. Brit. J. Haematol. 1980; 45: 107.
    CrossrefPubMedGoogle Scholar
  • 43 Dioguardi N., Mannucci P. M. Prothrom-bin-complex concentrate in liver disease. Lancet II 1975; 188.
    PubMedGoogle Scholar
  • 44 Dowing M. R., Butkowski R. J., Clark M. M., Mann K. G. Human prothrombin activation. J. Biol. Chem. 1975; 250: 8897.
    PubMedGoogle Scholar
  • 45 Edell S. Anaphylaxis after Konyne. New Engl. J. Med. 1971; 285: 580.
    PubMedGoogle Scholar
  • 46 Edson J. R. Prothrombin-complex concentrates and thrombosis. New Engl. J. Med. 1974; 290: 403.
    CrossrefPubMedGoogle Scholar
  • 47 Eggeling B., Lechler E., Asbeck F. Untersuchungen kommerzieller Präparationen des Prothrombinkomplexes (PPSB) auf aktivierte Faktoren. Verh. Dtsch. Ges. inn. Med. 1975; 81: 1140.
    PubMedGoogle Scholar
  • 48 Ekert H., Price D. A., Lane J. L., Dean F. L. A randomized study of factor VIII or prothrombin complex concentrate infusions in children with haemophilia and antibodies to factor VIII. Aust. N. Z. Med. 1979; 9: 241.
    CrossrefPubMedGoogle Scholar
  • 49 Elödi E., Váradi K. Activation of clotting factors in prothrombin complex concentrates as demonstrated by clotting assays for factors IXa and Xa. Thromb. Res. 1978; 12: 797.
    CrossrefPubMedGoogle Scholar
  • 50 Esmon C. T., Jackson C. M. The conversion of prothrombin to thrombin. III. The factor Xa catalized activation of prothrombin. J. Biol. Chem. 1974; 249: 7782.
    CrossrefPubMedGoogle Scholar
  • 51 Esmon C. T., Stenflo J., Suttie J. W. A new vitamin K-dependent protein. J. Biol. Chem. 1976; 251: 3052.
    PubMedGoogle Scholar
  • 52 Esnouf M. P. Current perspectives of factor X. Bibl. haemat. 1978; 44: 75.
    PubMedGoogle Scholar
  • 53 Faria R., Fiumara N. J. Hepatitis B associated with Konyne. New Engl. J. Med. 1972; 287: 358.
    PubMedGoogle Scholar
  • 54 Thromboembolic complication of factor IX complex. FDA Drug Bull. 10 1980: 25
    PubMed
  • 55 Fischer M., Falkensammer C., Gauss P., Korp W., Kubiena K., Neubert J., Schnack H., Weissmann A. Anwendung eines neuen Prothrombinkomplex-Kon-zentrates bei Patienten unter Antikoagu-lantientherapie und Patienten mit Lebererkrankungen. Med. Welt 1973; 24: 1899.
    PubMedGoogle Scholar
  • 56 Frick P. G., Riedler G., Brögli H. Dose response and minimal daily requirement for vitamin K in man. J. Appl. Physiol. 1967; 23: 387.
    CrossrefPubMedGoogle Scholar
  • 57 Fuehrt J. H., Mahrer P. Myocardial infarction after factor IX therapy. J. Amer. Med. Ass. 1981; 245: 1455.
    CrossrefPubMedGoogle Scholar
  • 58 Gazzard B. G., Henderson J. M., Williams R. The use of fresh frozen plasma or a concentrate of factor IX as replacement therapy before liver biopsy. Gut 1975; 16: 621.
    CrossrefPubMedGoogle Scholar
  • 59 Gazzard B. G., Lewis M. L., Ash G., Rizza C. R., Bidwell E., Williams R. Coagulation factor concentrate in the treatment of the haemorrhagic diathesis of fulminant hepatic failure. Gut 1974; 15: 993.
    CrossrefPubMedGoogle Scholar
  • 60 Gilchrist G. S., Ekert H., Shanbrom E., Hammond D. Evaluation of a new concentrate for the treatment of factor IX deficiency. New Engl. J. Med. 1969; 280: 291.
    CrossrefPubMedGoogle Scholar
  • 61 Göbel U., Petrich C. Zur Therapie der Blutungsneigung bei Vitamin-K-Mangel oder Leberfunktionsstörung im Säuglingsalter. Mschr. Kinderheilk. 1974; 122: 60.
    PubMedGoogle Scholar
  • 62 Graham J. B. Stuart clotting defect and Stuart factor. Thromb. Diathes. haemorrh. Suppl. ad 1960; 4: 22.
    PubMedGoogle Scholar
  • 63 Grammens G. L., Breckenridge R. T. Complications with Christmas factor (factor IX) concentrates. Ann. Intern. Med. 1974; 80: 666.
    CrossrefPubMedGoogle Scholar
  • 64 Green G., Poller L., Dymock I. W., Thomsen J. M. Use of factor-VII-rich prothrombin complex concentrate in liver disease. Lancet I 1975; 1311.
    PubMedGoogle Scholar
  • 65 Griffin J. H., Evat B., Zimmerman T. S., Kleiss A. C., Wideman C. Deficiency of protein C in congenital thrombotic disease. J. Clin. Invest. 1981; 68: 1370.
    CrossrefPubMedGoogle Scholar
  • 66 Guillin M.C., Ménaché D., Barge J., Rueff B., Fauvert R. Les troubles de l'hémostase au cours des hépatites virales graves: Etudes clinique anatomique et histologique. Ann. Med. Interne (Paris) 1971; 122: 605.
    PubMedGoogle Scholar
  • 67 Gunay U., Choi H. S., Maurer H. S., Hruby M., Honig G. R. Commercial preparations of prothrombin complex. Amer. J. Dis. Child. 1973; 126: 775.
    CrossrefPubMedGoogle Scholar
  • 68 Haanen C., McShine R. L., Kunst A. Preparation and clinical use of factor IX concentrate PPSB according to Soulier. Vox Sang 1969; 16: 398.
    CrossrefPubMedGoogle Scholar
  • 69 Hellerstein L. J., Deykin D. Hepatitis after Konyne administration. New Engl. J. Med. 1971; 284: 1039.
    PubMedGoogle Scholar
  • 70 Hemker H.C., Esnouf M. P., Hemker P. W., Swart A. C. W., Macfar-lane R. G. Kinetics of the formation of prothrombin converting activity in a purified system. Nature 1967; 215: 248.
    CrossrefPubMedGoogle Scholar
  • 71 Hemker H.C., Kahn M. J. P. Reaction sequence of blood coagulation. Nature 1967; 215: 1201.
    CrossrefPubMedGoogle Scholar
  • 72 Heystek J., Brummelhuis H. G. J., Krijnen H. W. Contributions to the optimal use of human blood. Vox Sang 1973; 25: 113.
    CrossrefPubMedGoogle Scholar
  • 73 Hoag M. S., Johnson F. F., Robinson J. A., Aggeler P. M. Treatment of hemophilia B with a new clotting-factor concentrate. New Engl. J. Med. 1969; 280: 581.
    CrossrefPubMedGoogle Scholar
  • 74 Hoofnagle J. H., Aronson D., Roberts H. Serologic evidence for hepatitis B virus infection in patients with hemophilia B. Thromb. Diathes. haemorrh. 1975; 33: 606.
    PubMedGoogle Scholar
  • 75 Hoppe I. Hepatitis auslösende Faktoren bei kardiochirurgischen Eingriffen. In Frösner G, Lasch H.-G., Lechler E. (Hrsg.): Plasmaproteine und Virushepatitis 33 Springer; Berlin, Heidelberg, New York: 1982
    Google Scholar
  • 76 Hougie C, Denson K. W. E., Bigs R. A study of the reaction product of factor VIII and factor IX by gel filtration. Thrombos. Diathes. haemorrh. 18: 211 1967;
    PubMedGoogle Scholar
  • 77 Huitín M. B. Activated clotting factors in factor IX concentrates. Blood 1979; 54: 1028.
    PubMedGoogle Scholar
  • 78 Hultin M. B., Nemerson ć. Activation of factor X by factor IX a and VIII; a specific assay for factor IX a in the presence of thrombin-activated factor VIII. Blood 1978; 52: 928.
    PubMedGoogle Scholar
  • 79 Jackson C. M., Suttie J. W. Recent developments in understanding the mechanism of vitamin K and vitamin K antagonist drug action and the consequence of vitamin K action in blood coagulation. Progr. Hematol. 1977; 10: 233.
    PubMedGoogle Scholar
  • 80 Jesty J. The inhibition of activated bovine coagulation factors X and VII by anti-thrombin III. Arch. Biochem. Biophys. 1978; 185: 165.
    CrossrefPubMedGoogle Scholar
  • 81 Kalousek F., Konigsberg W., Nemerson Y. Activation of factor IX by activated factor X: a linkage between the extrinsic and intrinsic coagulation systems. FEBS Lett. 1975; 50: 382.
    CrossrefPubMedGoogle Scholar
  • 82 Kasper C. K. Postoperative thrombosis in hemophilia B. New Engl. J. Med. 1973; 289: 160.
    PubMedGoogle Scholar
  • 83 Kasper C. K. Blood - Its derivatives and its problems - factor IX. Ann. N. ć. Acad. Sci. 1975; 240: 172.
    PubMedGoogle Scholar
  • 84 Kasper C. K. Thromboembolic complications. Thrombos. Diathes. haemorrh. 1975; 33: 640.
    PubMedGoogle Scholar
  • 85 Kelly P., Penner J. A. Antihemophilic factor inhibitors. Management with prothrombin complex concentrates. J. Amer. Med. Ass. 1976; 236: 2061.
    CrossrefPubMedGoogle Scholar
  • 86 Kingdon H. S. Evolution of enzyme activities and fibrin formation after contact of plasma with glass. J. Biomed. Mater. Res. 1969; 3: 25.
    CrossrefPubMedGoogle Scholar
  • 87 Kingdon H. S., Lundblad R. L., Veltkamp J. J., Aronson D. L. Potentially thrombogenic material in factor IX concentrates. Thrombos. Diathes. haemorrh. 1975; 33: 617.
    PubMedGoogle Scholar
  • 88 Kurczynski E. M., APenner J. Activated prothrombin complex for patients with factor VIII inhibitors. New Engl. J. Med. 1974; 291: 164.
    CrossrefPubMedGoogle Scholar
  • 89 Lane J. L., Rizza C. R., Snape T. J. A five-year experience of the use of factor IX type DE(1) concentrate for the treatment of Christmas disease at Oxford. Brit. J. Haematol. 1975; 30: 435.
    CrossrefPubMedGoogle Scholar
  • 90 Lechler E. Das Problem der Throm-bogenität bei der Substitutionstherapie mit Konzentraten vom PPSB-Typ. Forschg. erg. Transf. med. Immunhämatol. 1978; 4: 89.
    PubMedGoogle Scholar
  • 91 Lechler E., Eggeling B. Die potentiell thrombogene Wirkung von Prothrombin-Komplex-Präparaten und ihre Wirkung bei der Hemmkörperhämophilie. In Schumacher K, Grosser K.-D. (Hrsg.) Aktuelle Probleme der inneren Medizin. S.283. Schattauer; Stuttgart: 1977
    Google Scholar
  • 92 Lechler E., Nenci G. G. Gelfiltration der Faktoren IX und X: Änderung des Filtrationsverhaltens nach Aktivierung. In Lüscher E. F. (Hrsg.) Die Rolle der Blutplättchen bei der Thrombose. Das Problem der Hyperkoagulabilität, S. 193. Schattauer; Stuttgart, New York: 1976
    Google Scholar
  • 93 Lechner K. Coagulation abnormalities in liver disease. Sem. Thromb. Hemost. 1977; 4: 40.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 94 Loeliger E. A., Hensen A., Matern M. J., Veitkamp J. J., Bruning P. F., Hemker H. C. Treatment of haemophilia B with purified factor IX (PPSB). Folia Med. Neerl. 1967; 10: 112.
    PubMedGoogle Scholar
  • 95 Lowe G. D. O., Harvie A., Forbes C. D., Prentice C. R. M. Successful treatment with prothrombin complex concentrate of postoperative bleeding in a haemophiliac with a factor VIII inhibitor. Brit. med. J. 1976; 2: 1110.
    PubMedGoogle Scholar
  • 96 Ludwig E., Lechner K. Prophylaktische Behandlung bei schwerer Hämophilie B mit einem Faktor-IX-Konzentrat. Dtsch. med. Wschr. 1974; 99: 1355.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 97 Lusher J. M., Shapiro S. S., Palascak J. P., Vijaya Rao A., Levine P. H., Blatt P. M. The hemophilia study group: Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. New Engl. J. Med. 1980; 303: 421.
    CrossrefPubMedGoogle Scholar
  • 98 Machin S. J., Miller B. R. Thrombosis and factor IX concentrates. Lancet 1978; 1: 1367.
    PubMedGoogle Scholar
  • 99 Magnusson S., Sottrup-Jensen L., Petersen T. E., Morris H. R., Dell A. Primary structure of the vitamin K-dependent part of prothrombin. FEBS Lett. 1974; 44: 189.
    CrossrefPubMedGoogle Scholar
  • 100 Mannucci P. M., Franchi F., Dioguardi N. Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet II 1976; 542.
    PubMedGoogle Scholar
  • 101 Marchesi S. L., Burney L. Letter. New Engl. J. Med. 1974; 290: 403.
    CrossrefPubMedGoogle Scholar
  • 102 Marassi A., Manzullo V., diCarto V., Mannucci P. M. Thromboembolism following prothombin complex concentrates and major surgery in severe liver disease. Thromb. Haemost. 1978; 39: 787.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 103 Mariani G., Mannucci P. M., Maz-zucomi M. G., Capitanio A. Treatment of congenital factor VII deficiency with a new concentrate. Thromb. Haemost. 1978; 39: 675.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 104 Marlar R. A., Griffin J. H. Deficiency of protein C inhibitor in combined factor V/ VIII deficiency disease. J. Clin. Invest. 1980; 66: 1186.
    CrossrefPubMedGoogle Scholar
  • 105 Marlar R. A., Griffin J. H. Alternative pathways of thromboplastin-dependent activation of human factor X in plasma. Ann. N.Y. Acad. Sci. 1981; 370: 325.
    CrossrefPubMedGoogle Scholar
  • 106 Marlar R. A., Kleiss A. J., Griffin J. H. Human protein C: inactivation of factors V and VIII in plasma by the activated molecule. Ann. N.Y. Acad. Sci. 1981; 370: 303.
    CrossrefPubMedGoogle Scholar
  • 107 Ménaché D., Fauvert R., Soulier J.-P. Utilisation en hépatologie d'une fraction contenant la prothrombine le complex proconvertine-facteur Stuart et le facteur anti-hémiphilique B (P.P.B.). Path. Biol. 1959; 7: 2515.
    PubMedGoogle Scholar
  • 108 Middleton S. M., Bennett I. H., Smith J. K. A therapeutic concentrate of coagulation factors II IX and X from citrated, factor VIII-depleted plasma. Vox Sang 1973; 24: 441.
    PubMedGoogle Scholar
  • 109 Miura Y., Abe T., Kazama M., Yasuda J. A test method for the absence of throm-bogenicity in factor IX complex. Develop. biol. Stand. 1979; 44: 189.
    PubMedGoogle Scholar
  • 110 O'Connor M. L., Meck E. S., Simmons A. Detection of HBsAg in coagulation factor IX concentrates. Transfusion 1977; 17: 44.
    CrossrefPubMedGoogle Scholar
  • 111 O'Leary D., Ruymann F. B., Conrad M. Therapeutic approaches to factor X deficiency with emphasis on the use of a new clotting factor concentrate (Konyne). J. Lab. Clin. Med. 1971; 77: 23.
    PubMedGoogle Scholar
  • 112 O'Reilly R. A. Anticoagulant antithrombotic and thrombolytic drugs. In: Good-man-Gilman A., Goodman L. S., Gil-man A. (Eds.): The pharmacological basis of therapeutics 1347 6th edition MacMil-lan Publishing Co.INC; New York: 1980
    Google Scholar
  • 113 Osterud B., Bouma B. N., Griffin J. H. Human blood coagulation factor IX. J. Biol. Chem. 1978; 253: 5946.
    PubMedGoogle Scholar
  • 114 Osterud B., Miller-Andersson M., Abildgaard U., Prydz H. The effect of anti-thrombin III on the activity of the coagulation factors VII. IX and X. Thromb. Haemost. 1976; 35: 295.
    PubMedGoogle Scholar
  • 115 Østerud B., Rapaport S. I. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc. Natl. Acad. Sci. 1977; 74: 5260.
    CrossrefPubMedGoogle Scholar
  • 116 Østerud B., Schiffman S. Gel filtration of factors II, VII, IX, IXa and X. Thromb. Diathes. haemorrh. 1972; 28: 317.
    PubMedGoogle Scholar
  • 117 Penner J. A. Prothrombin complex concentrates. Bibl. haemat. 1978; 44: 81.
    PubMedGoogle Scholar
  • 118 Penner J. A., Abildgaard C. F. Ineffectiveness of certain commercial prothrombin complex concentrates in treatment of patients with inhibitors of factors VIII and IX. New Engl. J. Med. 1979; 300: 565.
    PubMedGoogle Scholar
  • 119 Preston F. E., Malia R. G., Lilley-man J. S., Blackburn E. K. Heparinized clotting factor concentrates in patients with Christmas disease and liver disease. Thromb. Haemost. 1977; 38: 504.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 120 Preston F. E., Winfield D. A., Malia R. G., Blackburn E. K. Serial changes in the coagulation system following clotting factor concentrate infusion. Thromb. Diathes. haemorrh. 1975; 34: 475.
    PubMedGoogle Scholar
  • 121 Prowse C. V., Cash J. D. The use of factor IX concentrates in man: a 9-year experience of Scottish concentrates in the south-east of Scotland. Brit. J. Haematol. 1981; 47: 91.
    CrossrefPubMedGoogle Scholar
  • 122 Radcliffe R., Nemerson Y. Mechanism of activation of bovine factor VII. J. Biol. Chem. 1976; 251: 4797.
    PubMedGoogle Scholar
  • 123 Rizza C. R., Spooner R. J. D. Home treatment of haemophilia and Christmas disease: five year's experience. Brit. J. Haematol. 1977; 37: 53.
    PubMedGoogle Scholar
  • 124 Roberts H. R., Lechler E., Webster W. P., Penick G. D. Survival of transfused factor X in patients with Stuart disease. Thromb. Diathes. haemorrh. 1965; 13: 305.
    PubMedGoogle Scholar
  • 125 Rosenberg R. D., Damus P. S. The purification and mechanism of action of human antithrombin-heparin cofactor. J. Biol. Chem. 1973; 248: 6490.
    PubMedGoogle Scholar
  • 126 Rosenberg J. D., McKenna P. W., Rosenberg R. D. Inhibition of human factor IXa by human antithrombin. J. Biol. Chem. 1975; 250: 8883.
    PubMedGoogle Scholar
  • 127 Rossiter S. J., Miller D. C., Raney A. A., Oyer P. E., Reitz B. A., Stinson E. B., Shumway N. E. Hepatitis risk in cardiac surgery patients receiving factor IX concentrates. J. Thorac. Cardiovasc. Surg. 1979; 78: 203.
    PubMedGoogle Scholar
  • 128 Sandler S. G., Rath C. E., Ruder A. Prothrombin complex concentrates in acquired hypoprothrombinemia. Ann. Intern. Med. 1973; 79: 485.
    CrossrefPubMedGoogle Scholar
  • 129 Schimpf K., Baumann P. Die ambulante Dauerbehandlung der Hämophilie B. Dtsch. med. Wschr. 1976; 101: 233.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 130 Schimpf K., Zimmermann K., Kömpf B. DIC and postoperative wound bleeding under factor IX substitution therapy in a case of haemophilia B successful treatment with heparin. Thromb. Res. 1976; 8: 65.
    CrossrefPubMedGoogle Scholar
  • 131 Di Scipio R. G., Hermodson M. A., Yates S. G., Davie E. W. A comparison of human prothrombin factor IX (Christmas factor), factor X (Stuart factor), and protein. S. Biochem. 1977; 16: 698.
    PubMedGoogle Scholar
  • 132 Scipio Di, Kurachi K., Davie E. W. Activation of human factor IX (Christmas factor). J. Clin. Invest 1978; 61: 1528.
    CrossrefPubMedGoogle Scholar
  • 133 Seeler R. A., Telischi M., Lengehen-nig P. L., Ashenhurst J. B. Comparison of anti-A and anti-B titers in factor VIII and IX concentrates. J. Pediatr. 1976; 89: 87.
    CrossrefPubMedGoogle Scholar
  • 134 Seligsohn U., Kasper C. K., Osterud B., Rapaport S. I. Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979; 53: 828.
    PubMedGoogle Scholar
  • 135 Shah D. V., Suttie J. W. The vitamin K-dependent in vitro production of prothrombin. Biochem. Biophys. Res. Comm. 1974; 60: 1397.
    CrossrefPubMedGoogle Scholar
  • 136 Smith J. K., Bidwell E. Therapeutic material used in the treatment of coagulation defects. Clin. Haematol. 1979; 8: 183.
    PubMedGoogle Scholar
  • 137 Soulier J. P., Blatrix C., Steinbuch M. Fractions »coagulantes« contenant les facteurs de coagulation adsorbables par le phosphate tricalcique. Presse méd. 1964; 72: 1223.
    PubMedGoogle Scholar
  • 138 Soulier J. P., Josso F., Steinbuch A Cosson M. The therapeutic use of fraction P. P.S.B. Bibl. haemat. 1968; 29: 1127.
    PubMedGoogle Scholar
  • 139 Soulier J.-P., Prou-Wartelle O., Josso F. Demi-vie de la prothrombine vraie (fac teur II). Nouv. Rev. Fr. Hématol. 1962; 2: 673.
    PubMedGoogle Scholar
  • 140 Soulier J. P., Prou-Wartelle O., Josso F. Demi-vie de la prothrombine vraie (facteur II). Bibl. haemat. 1964; 19: 156.
    PubMedGoogle Scholar
  • 141 Steinberg M. H., Dreiling B. J. Vascular lesions in hemophilia B. New Engl. J. Med. 1974; 289: 592.
    PubMedGoogle Scholar
  • 142 Stenflo J. A new vitamin K-dependent protein. J. Biol. Chem. 1976; 251: 355.
    PubMedGoogle Scholar
  • 143 Stenflo J., Fernlund P., Egan W. Vitamin K dependent modification of glutamic acid residues in prothrombin. Proc. Natl. Acad. Sci. USA 1974; 71: 2730.
    CrossrefPubMedGoogle Scholar
  • 144 Stenflo J., Suttie J. W. Vitamin K-dependent formation of gamma-carboxyglutamic acid. Ann. Rev. Biochem. 1977; 46: 157.
    CrossrefPubMedGoogle Scholar
  • 145 Strauss H. S. Surgery in patients with congenital factor VII deficiency (congenital hypoproconvertinemia). Blood 1965; 25: 325.
    PubMedGoogle Scholar
  • 146 Suomela H., Myllyä G., Raaska E. Preparation and properties of a therapeutic factor IX concentrate. Vox Sang 1977; 33: 37.
    CrossrefPubMedGoogle Scholar
  • 147 Suttie J. W., Hageman J. M., Lehr-man S. R., Rich D. H. Vitamin K-dependent carboxylase. Development of a peptide substrate. J. Biol. Chem. 1976; 251: 5837.
    PubMedGoogle Scholar
  • 148 Suttie J. W., Jackson C. M. Prothrombin structure activation and biosynthesis. Physiol. Rev. 1977; 57: 1.
    CrossrefPubMedGoogle Scholar
  • 149 Taberner D. A., Thomsen J. M., Poller L. Comparison of prothrombin complex concentrates and Vitamin K1 in oral anticoagulant reversal. Brit. med. J. 1976; 2: 83.
    CrossrefPubMedGoogle Scholar
  • 150 Tilsner V., Greul W. Behandlung von Blutungskomplikationen unter Antikoa-gulantientherapie mit Cumarinen. Med. Welt 1975; 26: 2332.
    PubMedGoogle Scholar
  • 151 Trobisch H., Schmitz L., Richter O. Identifizierung proteolytischer Enzyme in Pro-thrombinkonze'ntraten. In Schimpf, K. (Hrsg.): Fibrinogen, Fibrin und Fibrinkleber. Nebenwirkungen der Therapie mit Gerinnungsfaktorenkonzentraten, S. 348. Schattauer, Stuttgart; New York: 1980
    Google Scholar
  • 152 Tullis J. L., Merlin M., Jurigian P. Clinical use of human prothrombin complexes. New Engl. J. Med. 1965; 273: 667.
    CrossrefPubMedGoogle Scholar
  • 153 Varadi K., Hemker H. C. Kinetics of the formation of the factor X activating enzyme of the blood coagulation system. Thromb. Res. 1976; 8: 303.
    CrossrefPubMedGoogle Scholar
  • 154 Waltl H, Kurz R., Mitterstieler G., Födisch H. J., Hohenauer L., Rössler H. Intracranial haemorrhage in low-birth-weight infants and prophylactic administration of coagulation-factor concentrate. Lancet I 1973: 1248
    Google Scholar
  • 155 Weinreb N. L., Minsky N. Serious reaction after Konyne. New Engl. J. Med. 1971; 285: 1151.
    PubMedGoogle Scholar
  • 156 White G. C., Lundblad R. L., Kingdon H. S. Prothrombin complex concentrates: preparation properties, and clinical use. Curr. Top. Hematol. 1979; 2: 203.
    PubMedGoogle Scholar
  • 157 White G.C., Roberts H. R., Kingdon H. S., Lundblad R. L. Prothrombin complex concentrates: potentially throm-bogenic materials and clues to the mechanism of thrombosis in vivo. Blood 1977; 49: 159.
    PubMedGoogle Scholar
  • 158 Wyke R. J., Thornton A., Portmann B., Zuckerman A. J., Tsiquaye K. N., White Y., Das P. K., Williams R. Transmission of non-A non-B Hepatitis to chimpanzees by factor-IX concentrates after fatal complications in patients with chronic liver disease. Lancet I 1979; 520.
    PubMedGoogle Scholar
  • 159 Yin E. T., Wessler S., Stoll P. J. Identity of plasma activated factor X inhibitor with antithrombin III and heparin cofactor. J. Biol. Chem. 1971; 246: 3712.
    PubMedGoogle Scholar
  • 160 Yorke A. J. Factor VII deficiency and surgery. Is preoperative replacement necessary?. J. Amer. Med. Ass. 1977; 238: 424.
    CrossrefPubMedGoogle Scholar
  • 161 Zauber N. P., Levin J. Factor IX levels in patients with hemophilia B (Christmas disease) following transfusion with concentrates of factor IX or fresh frozen plasma (FFP). Medicine (Baltimore) 1977; 56: 213.
    CrossrefPubMedGoogle Scholar